Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Visual Emphysema as a Category Modifier in Lung-RADS: Secondary Analysis of National Lung Screening Trial.

About this Publication
Title
Visual Emphysema as a Category Modifier in Lung-RADS: Secondary Analysis of National Lung Screening Trial.
Pubmed ID
40049568 (View this publication on the PubMed website)
Digital Object Identifier
Publication
J Am Coll Radiol. 2025 Mar 4
Authors
Jang S, Kim J, Lee S, Kim YW, Kim J, Lee KW, Lee CT
Affiliations
  • Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Electronic address: radio622@gmail.com.
  • Institute of Health and Environment, Seoul National University, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Abstract

OBJECTIVE: The Lung CT Reporting and Data System (Lung-RADS) does not consider emphysema, a lung cancer risk factor detectable on CT, when assessing nodule risk. This study aimed to evaluate the impact of incorporating emphysema into Lung-RADS on lung cancer diagnosis.

METHODS: In this secondary analysis of the National Lung Screening Trial data, CT arm participants with noncalcified nodules were assigned to Lung-RADS categories, and their emphysema severity was visually dichotomized. Lung cancer rates within each Lung-RADS category were compared based on emphysema severity. A modified Lung-RADS, reclassifying nodules with significant emphysema into a higher category, was evaluated against standard Lung-RADS.

RESULTS: A study of 9,444 participants (782 [8.3%] with lung cancer) revealed difference in lung cancer rates across Lung-RADS categories based on visual emphysema severity: category 2 (2.6% versus 4.9%; P = .007), 3 (4.9% versus 9.0%; P < .001), 4A (9.2% versus 15.5%; P = .01), 4B (16.1% versus 24.1%; P = .12), and 4X (25.3% versus 33.2%; P = .008) without or with significant emphysema. Compared with standard Lung-RADS, modified Lung-RADS demonstrated a comparable area under the curve (0.73 versus 0.74, P = .009), increased sensitivity (61.3% versus 67.6%, P < .001), decreased specificity (77.2% versus 71.4%, P < .001), and improved goodness of fit (P = .008) for predicting lung cancer.

DISCUSSION: Lung cancer rates differ by emphysema severity within Lung-RADS categories. Using the visual emphysema severity as a category modifier in Lung-RADS increased sensitivity while achieving comparable area under the curve for lung cancer.

Related CDAS Studies
Related CDAS Projects